Tuning siRNA Packing Order in Lipid Nanoparticles Controls Oligonucleotide Functional Delivery

bioRxiv (Preprint) International

Overview

This preprint investigates how tuning the siRNA packing order within lipid nanoparticles (LNPs) can modulate oligonucleotide functional delivery, addressing a key challenge in RNA therapeutics: extrahepatic targeting. While LNPs are established carriers for RNA, achieving cell-specific and non-liver delivery remains difficult. This research suggests that optimizing the internal structure of LNPs, specifically the packing state of siRNA, significantly impacts their ability to deliver siRNA effectively, potentially enhancing both target specificity and extrahepatic distribution.

In Depth

Background: The Challenge of Extrahepatic RNA Delivery with LNPs

Small interfering RNAs (siRNAs) and other oligonucleotides represent a revolutionary class of therapeutics with the potential to treat diseases by specifically silencing gene expression. Lipid nanoparticles (LNPs) have emerged as the most successful and widely adopted delivery system for these nucleic acid medicines, enabling the clinical translation of several RNA therapeutics. However, a major limitation of current LNP technology is its predominant accumulation in the liver following systemic administration, a phenomenon known as hepatotropism. This intrinsic liver tropism severely restricts the therapeutic application of LNPs to extrahepatic organs or specific cell types, posing a significant barrier to broader clinical utility.

Key Findings / Results: Modulating Delivery Through Internal Structure

• Importance of siRNA Packing within LNPs: This research explores a novel approach to overcome LNP hepatotropism and improve extrahepatic targeting: precisely tuning the “packing order” of siRNA within the LNP core. The internal architecture of LNPs, including the condensation state and packing density of the nucleic acid cargo, is known to profoundly influence LNP stability, cellular uptake efficiency, and the critical step of endosomal escape, which is necessary for the siRNA to reach its intracellular target.
• Modulation of Oligonucleotide Functional Delivery: The preprint provides data suggesting that by exploring different lipid compositions and formulation conditions, researchers can intentionally control the packing order and arrangement of siRNA within the LNP. This optimization of the internal structure, in turn, influences the intracellular release of siRNA, its binding to target mRNA, and ultimately the gene silencing effect (functional delivery). For instance, specific packing states might facilitate more efficient endosomal escape, a rate-limiting step for many LNP-mediated therapies.
• Implications for Cell-Specific and Extrahepatic Delivery: A primary goal of this research is to improve LNP delivery beyond the liver. The study postulates that the internal packing order of nucleic acids within LNPs can influence their behavior in different cell types and organs in vivo, thereby promoting cell-specific uptake and enhanced delivery to extrahepatic tissues. This finding is crucial for expanding the therapeutic window of RNA drugs to organs such as the lungs, heart, brain, spleen, and lymph nodes, where targeted delivery remains a significant unmet need.

Technical Significance & Outlook: A New Paradigm for LNP Design

This research is technically significant as it deepens our understanding of how the internal structural parameters of LNPs, specifically the nucleic acid packing state, dictate their functional delivery efficiency and biodistribution. The ability to precisely control siRNA packing order offers a new dimension of optimization strategies for next-generation LNP design. This fundamental insight can pave the way for developing more effective and safer RNA therapeutics specifically tailored for particular diseases or target cells. Moving forward, LNP engineering may evolve beyond just optimizing lipid compositions to include the deliberate engineering of the internal nucleic acid structure. This paradigm shift holds the promise of accelerating the clinical translation of RNA therapeutics for numerous diseases with high unmet medical needs and contributing to the realization of personalized medicine.